Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 7
1982 17
1983 11
1984 8
1985 7
1986 9
1987 8
1988 12
1989 16
1990 19
1991 29
1992 28
1993 39
1994 45
1995 50
1996 43
1997 53
1998 82
1999 82
2000 85
2001 69
2002 75
2003 77
2004 73
2005 88
2006 82
2007 66
2008 62
2009 61
2010 59
2011 53
2012 62
2013 45
2014 69
2015 58
2016 60
2017 46
2018 53
2019 34
2020 53
2021 48
2022 30
2023 29
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

1,861 results

Results by year

Filters applied: . Clear all
Page 1
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
Papi A, Chipps BE, Beasley R, Panettieri RA Jr, Israel E, Cooper M, Dunsire L, Jeynes-Ellis A, Johnsson E, Rees R, Cappelletti C, Albers FC. Papi A, et al. N Engl J Med. 2022 Jun 2;386(22):2071-2083. doi: 10.1056/NEJMoa2203163. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569035 Clinical Trial.
BACKGROUND: As asthma symptoms worsen, patients typically rely on short-acting beta(2)-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma exacerbations. The use of a fixed-dose combination of albuterol a …
BACKGROUND: As asthma symptoms worsen, patients typically rely on short-acting beta(2)-agonist (SABA) rescue therapy, but SABAs do not addre …
Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease.
Rhodes JM, Subramanian S, Flanagan PK, Horgan GW, Martin K, Mansfield J, Parkes M, Hart A, Dallal H, Iqbal T, Butterworth J, Culshaw K, Probert C. Rhodes JM, et al. Dig Dis Sci. 2021 Aug;66(8):2700-2711. doi: 10.1007/s10620-020-06477-y. Epub 2020 Jul 17. Dig Dis Sci. 2021. PMID: 32681228 Clinical Trial.
Including crossover, 39 patients received antibiotics/hydroxychloroquine and 39 received budesonide. At 10 weeks, 24 weeks, and 52 weeks on initial therapy, only 2/27, 2/27, and 1/27 were in remission on antibiotics/hydroxychloroquine compared with 8/32, 1/32, and 1/32 on …
Including crossover, 39 patients received antibiotics/hydroxychloroquine and 39 received budesonide. At 10 weeks, 24 weeks, and 52 we …
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M. Bafadhel M, et al. Lancet Respir Med. 2018 Feb;6(2):117-126. doi: 10.1016/S2213-2600(18)30006-7. Epub 2018 Jan 10. Lancet Respir Med. 2018. PMID: 29331313 Clinical Trial.
METHODS: We analysed data from three AstraZeneca randomised controlled trials of budesonide-formoterol in patients with COPD with a history of exacerbations and available blood eosinophil counts. ...Only eosinophil count and smoking history were independent predictors of r …
METHODS: We analysed data from three AstraZeneca randomised controlled trials of budesonide-formoterol in patients with COPD with a h …
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, Mane S, Vohlidkova A, Martindale J, Williams M, Shirtcliffe P, Holliday M, Weatherall M, Beasley R; PRACTICAL study team. Hardy J, et al. Lancet. 2019 Sep 14;394(10202):919-928. doi: 10.1016/S0140-6736(19)31948-8. Epub 2019 Aug 23. Lancet. 2019. PMID: 31451207 Clinical Trial.
Nasopharyngitis was the most common adverse event in both groups, occurring in 154 (35%) of 440 patients receiving as-needed budesonide-formoterol and 144 (32%) of 448 receiving maintenance budesonide plus terbutaline as needed. INTERPRETATION: In adults with mild t …
Nasopharyngitis was the most common adverse event in both groups, occurring in 154 (35%) of 440 patients receiving as-needed budesonide …
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.
Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Rabe KF, et al. Lancet. 2006 Aug 26;368(9537):744-53. doi: 10.1016/S0140-6736(06)69284-2. Lancet. 2006. PMID: 16935685 Clinical Trial.
After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one of three alternative as-needed medications-terbutaline (0.4 mg), formoterol (4.5 microg), or budesonide-formoterol (160 microg and 4.5 microg). ...The rate of severe exa …
After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one of three alternative as-needed medic …
Ciclesonide.
Reynolds NA, Scott LJ. Reynolds NA, et al. Drugs. 2004;64(5):511-9; discussion 520-1. doi: 10.2165/00003495-200464050-00005. Drugs. 2004. PMID: 14977388 Clinical Trial.
In two 12-week, randomised studies in patients with asthma, ciclesonide 80 or 320 microg once daily was at least as effective as budesonide 400 microg/day at increasing forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) from baseline; ciclesonide 3 …
In two 12-week, randomised studies in patients with asthma, ciclesonide 80 or 320 microg once daily was at least as effective as budesoni …
Randomised clinical trial: adjunctive induction therapy with oral effervescent budesonide in newly diagnosed coeliac disease.
Newnham ED, Clayton-Chubb D, Nagarethinam M, Hosking P, Gibson PR. Newnham ED, et al. Aliment Pharmacol Ther. 2021 Aug;54(4):419-428. doi: 10.1111/apt.16446. Epub 2021 Jun 28. Aliment Pharmacol Ther. 2021. PMID: 34181750 Clinical Trial.
METHODS: In a pilot, randomised, double-blind trial, effects on Marsh grading and quantitative duodenal morphometry of 10 weeks' effervescent budesonide (initially 9 mg/day) or placebo were assessed after 8 and 52 weeks. Multiple clinical measures and adverse events were a …
METHODS: In a pilot, randomised, double-blind trial, effects on Marsh grading and quantitative duodenal morphometry of 10 weeks' effervescen …
Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
Straumann A, Lucendo AJ, Miehlke S, Vieth M, Schlag C, Biedermann L, Vaquero CS, Ciriza de Los Rios C, Schmoecker C, Madisch A, Hruz P, Hayat J, von Arnim U, Bredenoord AJ, Schubert S, Mueller R, Greinwald R, Schoepfer A, Attwood S; International EOS-2 Study Group. Straumann A, et al. Gastroenterology. 2020 Nov;159(5):1672-1685.e5. doi: 10.1053/j.gastro.2020.07.039. Epub 2020 Jul 25. Gastroenterology. 2020. PMID: 32721437 Free article. Clinical Trial.
METHODS: We performed a double-blind trial to compare the efficacy and safety of 2 dosages of a budesonide orodispersible tablet (BOT) vs placebo in maintaining remission of EoE. ...
METHODS: We performed a double-blind trial to compare the efficacy and safety of 2 dosages of a budesonide orodispersible tablet (BOT …
Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
D'Haens GR, Kovács A, Vergauwe P, Nagy F, Molnár T, Bouhnik Y, Weiss W, Brunner H, Lavergne-Slove A, Binelli D, Di Stefano AF, Marteau P. D'Haens GR, et al. J Crohns Colitis. 2010 Jun;4(2):153-60. doi: 10.1016/j.crohns.2009.09.007. Epub 2009 Oct 24. J Crohns Colitis. 2010. PMID: 21122499 Clinical Trial.
METHODS: 36 patients were treated once daily for 4 weeks with Budesonide-MMX 9 mg tablets or placebo. In an additional 4-week period, all patients received Budesonide-MMX. ...The CAI reduction was significant with Budesonide (p<0.0001) tablets and not with …
METHODS: 36 patients were treated once daily for 4 weeks with Budesonide-MMX 9 mg tablets or placebo. In an additional 4-week period, …
1,861 results